Neoadjuvant and post-surgery immunotherapy for operable lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have operable NSCLC that can be surgically removed (stages IA3 to IIIA, with limited lymph node spread).
- Your scans show measurable cancer to track response (per RECIST).
- Your general health is good enough for treatment (ECOG 0 to 1).
- You have adequate blood/organ test results from samples taken within 14 days before starting.
- You can meet the trial’s birth control rules (and avoid pregnancy) during treatment and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This study tests whether doing surgery only after checking if the tumor shrinks with chemo-immunotherapy is safe and effective for people with locally advanced lung cancer. It may help avoid surgery if the cancer hasn't responded well.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.